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Abstract: The development of obesity and insulin resistance has been extensively studied 
in the last decades, but the mechanisms underlying these alterations are still not completely 
understood. The gut microbiota has been identified as a potential contributor to metabolic 
diseases. It has been shown that obese individuals present different proportions of bacterial 
phyla compared with lean individuals, with an increase in Firmicutes and Actinobacteria 
and  a  decrease  in  Bacteroidetes.  This  alteration  seems  to  interfere  with  intestinal 
permeability,  increasing  the  absorption  of  lipopolysaccharide  (LPS),  which  reaches 
circulation and initiates activation of Toll-like receptor (TLR) 4 and 2 and LPS receptor 
CD14, leading to increased activation of inflammatory pathways. With these activations, 
an impairment of the insulin signaling is observed, with decreased phosphorylation of the 
insulin receptor, insulin receptor substrate (IRS) and Akt, as well as increased inhibitory 
serine phosphorylation of IRS-1. Altered proportions of bacterial phyla have also been 
demonstrated to interfere with host’s biochemical pathways, increasing energy extraction 
and  depot  in  adipose  tissue.  Therefore,  understanding  the  mechanisms  by  which  the 
alteration  in  the  gut  microbiota  produces  different  signaling  activations  and  phenotype 
changes may offer an interesting opportunity for the treatment of obesity and type 2 diabetes. 
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1. Introduction 
The epidemics of obesity and type 2 diabetes mellitus in the past 20 years have led to numerous 
investigations concerning the mechanisms that are responsible for the development of these diseases. 
The general view is that insulin resistance is an early alteration of type 2 diabetes mellitus and obesity, 
and both diseases are strongly influenced by genetics and environment [1–5]. Moreover, studies in the 
past  ten  years  have  shown  that  low-grade  inflammation  has  an  important  role  in  the  molecular 
mechanism of insulin resistance in these diseases [6–10] and more recently (within the past five years)  
a  new  component  that  has  both  genetic  and  environmental  factors  is  also  being  studied:  the  gut  
microbiota [11–17].  
This  way,  a  paradigm  has  been  dismantled:  microorganisms  should  no  longer  be  associated  
with  pathogenesis,  since  both  bacteria  and  their  eukaryote  hosts  benefit  from  their  cooperative 
relationships  [18].  In  humans,  there  are  at  least  100  trillion  microbial  cells,  collectively  called 
microbiota,  distributed  in  complex  and  site-specific  communities.  As  the  genome  of  these  
bacteria—the microbiome—contains hundreds of genes that do not exist in the human genome [19], 
we can consider our symbionts as an important extra organ.  
This complex community—bacteria, eukaryotes, viruses and Archeae—in its majority cannot be 
cultured. The reasons for this limitation are unknown growth requirements of the bacteria, selectivity 
of the media that are used, stress imposed by the cultivation procedures, necessity of strictly anoxic 
conditions, and the difficulties on simulating the interactions of bacteria with other microbes and host 
cells  [20].  Thus,  a  new  approach  was  introduced,  culture-independent  sequencing  [21–23],  which 
made detection of microbial genes and disease-associated patterns in our gut microbiota possible. The 
bacterial component of the microbiota has been intensively studied in the past few years, including  
high-investment studies such as the Human Microbiome Project [24,25] and MetaHIT [26].  
Using this new approach made it possible to detect three dominating bacterial phyla in the human 
gastrointestinal  tract:  the  gram-positive  Firmicutes  and  Actinobacteria,  and  the  gram-negative 
Bacteroidetes. Firmicutes is known as the largest bacterial phylum, comprehending 200 genera, which 
includes Lactobacillus, Mycoplasma, Bacillus, and Clostridium. In spite of Actinobacteria being also a 
dominant  phylum,  it  is  usually  missed  by  RNA  gene  sequencing  and  can  only  be  detected  by 
fluorescent in situ hybridization [20,27]. 
Although gut microbiota has been described as relatively stable concerning its composition until old 
age [28–31], this temporal consistency considers that numerous variables are being held constant [32]. 
For example, dietary changes have been shown to have significant effects on the microbiota. Shifting 
mice to a high-fat, high-sugar ―Western‖ diet, from a low-fat, plant polysaccharide-rich diet, changed 
the  microbiota  within  24  h  [33].  Likewise,  shifting  from  a  high-fat/low-fiber  diet  caused  notable 
changes in the gut microbiota within a day [34]. 
2. Gut Microbiota Composition 
Recent  studies  have  associated  alterations  in  the  gut  microbiota  with  increased  energy  harvest  
and  storage,  and  increased  capacity  of  fermenting  and  absorbing  otherwise  undigested  
carbohydrates [27,35–37]. Moreover, the gut microbiota plays an important role in the development of Nutrients 2013, 5  831 
 
 
the immune system and helps maintain the intestinal homeostasis [38]. For instance, they are essential 
for the emergence of T cell subsets and the differentiation of gut B cells into IgA-producing plasma  
cells [39–42].  
The  early  establishment  of  the  gut  microbiota  begins  specially  during  birth,  when  babies  are 
exposed  to  innumerous  microbes  from  different  environments,  which  colonize  them  promptly. 
Depending on the delivery mode, babies are colonized by microbes from their mother’s vagina or from 
the skin [43,44]. The gastrointestinal tract is colonized first of all by facultative aerobes, then by 
anaerobes. When the facultative anaerobic bacteria populations grow, they consume the oxygen and 
generate  an  anaerobic  environment  [45].  In  the  first  week  of  life,  these  bacteria  form  a  reducing 
environment, which favors the succession of strict anaerobes. 
Supporting the view that the environment is extremely relevant for  the composition of the gut 
microbiota  and  sometimes  preponderant  to  the  genetic  predisposition  [46],  a  study  comparing 
dizygotic  and  monozygotic  twins  revealed  that  there  is  no  significant  difference  in  the  degree  of 
similarity in their gut microbiota [47]. Moreover, a study performing co-housing [48] has shown that it 
is possible to exacerbate a phenotype by exchanging different gut microbiota between mice that had 
been raised separately and put together in the same cage after a period of time.  
Another  environmental  factor  that  can  profoundly  change  the  microbiota  profile  is  the  use  of 
antibiotics. Several studies have shown that treatment with antibiotics leads to major alterations in the 
gut  microbiota  composition  [46,49–52].  After  treatment  with  antibiotics,  a  reduced  resistance  to 
colonization is observed, permitting that foreign microbes grow and lead to permanent changes in the 
structure of the microbiota. This alteration can even cause diseases [32]. Although the altered taxa are 
different among individuals, some of them are not able to recover months after treatment and there is 
decrease in the bacterial diversity in most of the cases studied.  
A subtherapeutic antibiotic therapy, shown by Cho and colleagues [52], led to exposure of microbiota 
with increased metabolic activity that were able to extract a higher proportion of calories from dietary 
complex  carbohydrates  that  were  relatively  indigestible  in  the  control  mice.  This  treatment  also 
induced increase in short-chain fatty acids production, which are the metabolic product of this activity 
and  may  be  delivered  in  increased  quantities  through  the  portal  circulation  of  the  liver,  enabling 
enhanced lipogenesis. This study indicates the possibility that modulation of the infant gut microbiome 
by antibiotics could have long-term consequences affecting adiposity and bone development [52]. 
3. The Development of Obesity is Influenced by Gut Microbiota Composition 
Obesity has also been correlated with reduced bacterial diversity, altered expression of bacterial 
genes, and metabolic pathways [36]. Obese individuals have a differential proportion of particular 
phyla  in  their  gut  microbiota:  fewer  Bacteroidetes  and  more  Firmicutes,  compared  with  lean  
controls [36,53]. Some studies, however, point that the decrease in Bacteroidetes is accompanied by an 
increase in Actinobacteria rather than Firmicutes [47]. We have shown that Toll-like Receptor (TLR)2 
knockout (KO) mice present increased relative proportion of Firmicutes and, slightly, of Bacteroidetes. 
However, these mice presented increased weight  gain  after 12 weeks  of age compared with  their 
controls and were obese after 20 weeks [46], suggesting that different proportions of bacterial phyla 
may lead to alterations that culminate in obesity. Nutrients 2013, 5  832 
 
 
The  Bacteroidetes  bins  were  shown  to  be  enriched  in  phosphotransferase  systems  involved  in 
microbial processing of carbohydrates, whereas the Firmicutes bins were shown to be enriched in 
transport systems. Seventy-five percent of the obesity-enriched genes were from Actinobacteria and 
twenty-five  percent  from  Firmicutes,  while  forty-two  percent  of  lean  enriched  genes  were  from 
Bacteroidetes. Functional analyses suggest that many of them were involved in carbohydrate, lipid, 
and amino acid metabolism [47,54]. These findings suggest that a core gut microbiome exists as shared 
genes, with important alterations in metabolic functions rather than alterations simply in the relative 
abundance of bacterial taxa [47].  
This shift in the relative abundance of phyla is associated with increased capacity for harvesting 
energy  from  food  and  with  increased  low-grade  inflammation.  The  increased  capacity  to  harvest 
energy  from  nutrients  observed  in  mice  with  increased  proportion  of  Firmicutes  and  decreased 
proportion of Bacteroidetes seems to be related to the presence of genes encoding enzymes that break 
down polysaccharides that cannot be digested by the host, consequently with increased production of 
more fermentation end-products, mainly short-chain fatty acids, and their conversion to triglycerides in 
the  liver.  Moreover,  regulation  of  host  genes  that  promote  deposition  of  lipids  in  adipocytes  has  
been  related  to  altered  gut  microbiota  composition.  The  microbiota  suppresses  the  expression  of  
fasting-induced  adipose  factor,  Fiaf,  a  secreted  lipoprotein  lipase  (LPL)  inhibitor.  By  suppressing  
Fiaf,  colonization  enhances  LPL  activity,  increasing  storage  of  liver-derived  triglycerides  [55].  
Turnbaugh et al. in a study with ob/ob mice found that reduced calorie content in the feces of ob/+ and 
+/+ littermates as compares with lean mice [27].  
However,  Backhed  et  al.  [56]  did  not  find  statistical  difference  between  germ-free  and 
conventionalized  mice  concerning  the  energy  content  in  their  feces;  this  observation  could  be 
explained  by  other  molecular  mechanisms,  as  mentioned  above.  Another  possible  mechanism 
suggested by this group would be the increased activation of AMP-activated protein kinase (AMPK) in 
the  skeletal  muscle  and  liver,  increasing  fatty  acid  oxidation  and  glucose  uptake  in  the  muscle. 
Phosphorylated  AMPK  stimulates  fatty  acid  oxidation  in  peripheral  tissues  by  phosphorylating 
acetylCoA carboxylase (Acc). Phosphorylation of Acc leads to inhibition of its activity, decreasing 
malonylCoA levels, which releases carnitine:palmitoyl transferase-1 (Cpt1). This enzyme catalyzes the 
rate limiting step for entry of long-chain fatty acylCoA into mitochondria, therefore increasing fatty 
acid oxidation [57]. 
This way, results from experiments performed in germ-free and Bacillus-associated wild-type (WT) 
mice  also  support  an  active  role  of  microbiota  in  modulating  fat  oxidation  and  accumulation, 
suggesting  that,  different  from  early  beliefs,  dietary  fats  alone  might  not  be  enough  to  cause 
overweight and obesity. It has been demonstrated that transplantation of gut microbiota from mice with 
obese  phenotype  to  germ-free  or  Bacillus-monoassociated  lean  WT  mice  leads  to  increased  body 
weight gain [27,46,58]. Turnbaugh and colleagues have shown that gut microbiota transplantation 
from mice with a mutation in the leptin gene—the ob/ob mice—to germ-free WT lean mice led to 
increase body weight gain [27]. Likewise, Vijay-Kumar and colleagues have shown that transplantation 
of gut microbiota from mice genetically deficient in Toll-like Receptor (TLR)5 to germ-free WT lean 
mice leads to weight gain and other signs of metabolic syndrome in the recipients [58]. However, in 
contrast with ob/ob mice, TLR5 deficient mice and WT littermate mice presented similar relative 
abundances of Firmicutes and Bacteroidetes. However, UniFrac analysis indicated that TLR5 deficient Nutrients 2013, 5  833 
 
 
mice and WT littermate mice were different in their species composition. Moreover, the knockout mice 
presented increased or decreased phylotypes from various phyla. We have shown that transplantation of 
gut microbiota from mice genetically deficient in TLR2 to Bacillus-monoassociated WT lean mice 
leads to weight gain, insulin resistance and impaired insulin signaling, resembling the phenotype found 
in TLR2 deficient mice [46]. These metabolic characteristics were also similar to what was found in 
TLR5  deficient  mice,  except  for  the  fact  that  TLR2  knockout  mice  did  not  present  hyperphagia. 
However, regarding the gut microbiota composition, TLR2 knockout mice were different from TLR5 
knockout mice, presenting increased relative abundance of Firmicutes compared with WT mice. 
It  has  also  been  suggested  that  obese  individuals  might  be  able  to  extract  more  energy  from 
nutrients due to hydrogen transfer between taxa, as a concurrent increase in both hydrogen-producing 
Prevotellaceae and hydrogen-utilizing methanogenic Archaea has been associated with obesity [59]. 
Another  study  corroborates  these  data,  showing  that  germ-free  mice  colonized  with  Bacteroides 
thetaiotaomicron, a saccharolytic member of the normal human colonic microbiota, together with the 
dominant  human  colonic  methanogen,  Methanobrevibacter  smithii,  have  increased  polysaccharide 
fermentation, increased de novo lipogenesis and enhanced host adiposity compared with animals with 
either organism alone [35] (Figure 1). 
Figure  1.  Alteration  in  gut  microbiota  composition  due  to  obesity  is  accompanied  by 
changes in activation of enzymes and pathways, leading to and increased inflammatory 
state and energy harvest. AMPK: AMP-activated kinase; SCFA: short-chain fatty acids; 
LPL: lipoprotein lipase; ACC: acetyl-CoA carboxylase; CPT1: carnitine palmitoyltransferase I. 
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4. Gut Microbiota in Type 2 Diabetic Individuals 
Recently, research has pointed out that the intestinal microbiome might be an important contributor 
for  the  development  of  type  2  diabetes  (T2D)  [60].  The  use  of  genome-wide  association  studies 
(GWAS)  has  achieved  many  elucidations  in  this  matter  [61,62].  Qin  et  al.  characterized  the  gut 
microbiota of T2D patients and observed increase in membrane transport of sugars, branched-chain 
aminoacids transport, methane metabolism, xenobiotics degradation, and sulphate reduction. However, 
they observed decrease in the levels of butyrate biosynthesis, bacterial chemotaxis, flagellar assembly, 
vitamins  and  cofactors  metabolism.  This  study  has  also  shown  that  the  gut  environment  of  T2D 
individuals is one that stimulates bacterial defense mechanisms against oxidative stress and against  
drugs [63]. 
Changes in the composition of the gut microbiota of obese individuals also implicate changes in the 
concentration  of  short-chain  fatty  acids  in  their  feces  [64].  Of  the  SCFA  produced  during  from 
microbial  fermentation  process,  butyrate  has  an  important  role  as  an  energy  substrate  for  cellular 
metabolism  in  the  colonic  epithelium,  while  acetate  and  propionate  are  taken  up  by  the  liver  as 
substrates for lipogenesis and glucogeneogenesis. These SCFA, especially butyrate, also contribute to 
modulation of  gene expression in  mammalian  colonic epithelial  cells.  As butyrate  acts  as  histone 
deacetylase inhibitor, it may regulate around 2% of the mammalian transcriptome [65]. For example, 
glucagon-like peptide (GLP)-1, a hormone with antidiabetic effects secreted by L-cells of the distal 
small intestine and colon, may have its secretion modulated by SCFA [66,67].  
Therefore,  diabetic  individuals  might  also  have  differential  secretion  of  hormones  due  to 
fermentation products of their altered gut microbiota. 
5. The Association between Insulin Resistance and Gut Microbiota 
Insulin is an essential hormone for the regulation of glucose homeostasis and initiates its biological 
effects through activation of the insulin receptor (IR), which occurs by autophosphorylation of IR [68], 
leading to tyrosine phosphorylation of several substrates such as the insulin receptor substrate (IRS)-1 
and -2 [69]. After tyrosine phosphorylation, IRS-1 and IRS-2 bind and activate phosphatidylinositol  
3-kinase (PI3-K) [69,70], which increases serine phosphorylation of Akt, leading to glucose transport 
in muscle and adipose tissue, glycogen synthesis in muscle and liver and lipogenesis in adipose tissue. 
The appropriate signaling of this pathway may be disrupted by several mechanisms. Some of them are: 
serine phosphorylation of IRS proteins by protein kinases such as c-Jun N-terminal kinase (JNK) and 
inhibitory κB kinase (IKK)-β, and decreased tyrosine phosphorylation of IRS-1 [71–76]. 
One of the important  mechanisms  by which JNK pathway can be activated is  by endoplasmic 
reticulum stress activation. In both adipose tissue and liver of mice chronically fed with a high-fat diet, 
PERK and IRE1α phosphorylation and JNK activity are significantly increased compared with lean 
animals [77]. 
The insulin signaling may also be impaired by altered secretion of cytokines and chemokines. For 
example, in type 2 diabetic patients, circulating T cells produce higher levels of IL-17 and IFN-γ, 
leading to a pro-inflammatory state [78]. Other cytokines, such as tumor necrosis factor (TNF)-α and 
interleukine (IL)-6, have also been related to insulin resistance. TNF-α protein is elevated is adipose Nutrients 2013, 5  835 
 
 
tissue from four different rodent models of obesity and diabetes and the inhibition of its expression  
leads to increased peripheral uptake of glucose. Likewise, modulation of TNF-α release from the cell  
surface  by  alteration  in  the  expression  of  TNF-α  converting  enzyme  (TACE),  a  disintegrin  and 
metalloproteinase,  or  of  tissue  inhibitor  of  matrix  metalloproteinase  3  (TIMP3)  leads  to  glucose 
intolerance and vascular inflammation or to hypermetabolic lean phenotype [79–81]. IL-6 can also 
affect insulin signaling: its plasma concentration is inversely proportional to insulin sensitivity, which 
is  hypothesized  by  IL-6-induced  suppressors  of  cytokine  signaling  (SOCSs)  expression.  SOCSs 
usually  act  suppressing  the  effect  of  cytokines  on  insulin  transduction  steps,  such  as  IRS-1 
phosphorylation, PI3K activation or PKB activation [82,83]. 
Similarly, the chemokine monocyte chemoattractant protein (MCP)-1, is associated with induction 
of insulin resistance and dedifferentiation of adipocytes. It is up-regulated by insulin resistance-inducing 
cytokines as IL-6 in adipocytes, representing a molecular connection between insulin resistance and 
obesity [84–86]. 
Moreover, insulin signaling can be affected by the activation of the innate immune system. Toll-like 
receptors (TLRs) play an important role in the activation of innate immune responses in mammals by 
recognizing conserved pathogen-associated molecular patterns [87–89]. There are at least 11 members 
of the TLR family in humans and 13 in mice [90]. TLRs play a crucial role in the recognition of 
invading pathogens and the activation of subsequent immune responses against them. Individual TLRs 
recognize distinct pathogen-associated molecular patterns. The TLR family harbors an extracellular 
leucine-rich  repeat  domain,  as  well  as  a  cytoplasmic  domain  that  is  homologous  to  that  of  the 
interleukin-1 receptor (IL1R1). Upon stimulation, TLR recruits IL1R1-associated protein kinases via 
adaptor MYD88 and finally induces the activation of nuclear factor-κB and mitogen-activated protein 
kinases, as well as the expression of inflammatory cytokines [91–93]. 
TLR4 is a subclass of TLRs that can be activated by lipopolysaccharide (LPS), a major component 
of the outer membrane in Gram-negative bacteria, and by nonbacterial agonists, such as saturated fatty 
acids  [73,94].  The  activation  of  TLR4  signaling  induces  upregulation  of  inflammatory  pathways 
related to the induction of insulin resistance, such as c-Jun NH2-terminal kinase (JNK) and IκB kinase  
complex  (IKKβ)/inhibitor  of  nuclear  factor-κB  (IκBα)/nuclear  factor-κB  (NF-κB)  [87,95],  while  
loss-of-function mutation and knockout in TLR4 prevents insulin resistance induced by obesity or free 
fatty  acids,  suggesting  an  important  role  of  TLR4  in  the  interface  of  innate  immune  system  and 
energetic metabolism [95–102] (Figure 2).  
In  adipocytes,  two  different  mechanisms  also  contribute  to  LPS-induced  insulin  resistance. 
Activation of TLR4 by LPS in preadipocytes increases the expression of several cytokines, mainly  
TNF-α and IL-6, impairing the insulin signaling in adipocytes [103]. LPS can also promote expression 
of NF-κB and activation of MAPK pathway in adipocytes with several target genes [14]. Moreover, a 
study has suggested that LPS can promote the expression of iNOS [97,103], which is also known as 
capable of interfering with the insulin signaling [104]. The effect of nitric oxide on insulin action may 
be  worsened  by  the  increase  of  LPS-induced  release  of  TNF-α  and  IL-6.  Moreover,  excessive 
production of nitric oxide worsens insulin resistance by increasing levels of circulating fatty acids, due 
to hampering LPL activity and increasing of lipolysis [105]. Nutrients 2013, 5  836 
 
 
Figure  2.  Insulin  signaling  is  affected  by  Toll-like  Receptor  (TLR)2  and  4  signaling.  
LPS: lipopolysaccharide; IRS: insulin receptor substrate; PI3K: phosphoinositide 3-kinase; 
AKT:  protein  kinase  B;  IKK:  IκB  kinase;  JNK:  c-Jun  N-terminal  kinase;  MyD88:  
Myeloid differentiation primary gene response (88); MAL/TIRAP: MyD88 adapter-like;  
TRAF6:  TNFR-associated  factor  6;  IRAK:  interleukin-1  receptor-associated  kinase;  
TAK1: Transforming Growth Factor β-activated kinase 1. 
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Likewise,  TLR2  has  been  shown  as  an  important  modulator  of  insulin  resistance.  A  recent  study 
showed  that  palmitate  treatment  of  differentia ted  C2C12  myotubes  resulted  in  a  time -dependent 
inhibition of insulin-activated signal transduction, through TLR2 activation [106]. We have also shown 
that  short -term  inhibition  of  TLR2  expression  using  TLR2  oligonucletide  antisense  in  diet -induced 
obese  m ice  leads  to  increased  insulin  sensitivity  and  signaling  [107].  Other  studies  [108,109] have 
reported  that  TLR2  knockout  (KO)  mice  present  decreased  body  weight  and  adiposity,  are  protected 
against  insulin  resistance,  and  gain  less  weight  on  a  HFD  than  con trol  mice  and  are  also  protected 
against related comorbidities [55,110] (Figure 2).  
However,  we  have  found  an  opposite  metabolic  description  for  TLR2  knockout  mice.  TLR2  KO 
mice  in  conventionalized  conditions  in  our  breeding  center  have  insulin  resistance   and  glucose 
intolerance  associated  with  alterations  in  the  composition  of  the  gut  microbiota,  which  displayed  an 
increase in the relative abundance of Firmicutes and Bacteroidetes and decreased relative abundance of 
Proteobacteria, compared to their contr ols. The insulin resistance of TLR2 KO mice was accompanied Nutrients 2013, 5  837 
 
 
by a down-modulation of insulin-induced insulin signaling in the liver, muscle, and adipose tissue, 
associated  with  an  increase  in  endoplasmic  reticulum  stress.  These  metabolic  alterations  were 
characterized in eight-week-old TLR2 KO mice. At this age, knockout and WT mice had similar body 
weights. In spite of the fact that our knockout mice and those used in the other studies mentioned 
above had the same genetic background, they were bred in different rooms and fed with food from 
different  sources,  which  can  certainly  have  a  role  in  the  establishment  and  maintenance  of  gut 
microbiota [111]. This way, gut microbiota per se can subvert a genetically predetermined condition 
previously  described  as  being  protective  towards  obesity  and  insulin  resistance  into  a  phenotype 
associated with weight gain and its complications, such as glucose intolerance and diabetes [46]. 
Although the molecular origin of the state of low-grade inflammation found in obese individuals is 
unknown, LPS has been associated as the responsible one for the onset of metabolic diseases [97], 
since a continuous low-rate infusion of LPS induced most of the features of metabolic diseases, which 
did  not  occur  in  LPS  receptor  CD14  knockout  mice  [12].  Thus,  we  have  found  that  the  insulin 
resistance presented by TLR2 KO mice could be explained by the increased LPS serum levels, which 
led to increased activation of TLR4 in muscle, liver and adipose tissue, and increased phosphorylation 
of JNK, but not of IKK. Likewise, these mice presented reduced serum levels of proinflammatory 
citokynes IL-6 and TNF-α [46] (Figure 3). 
The absence of increased IKK pathway activation in our model was very intriguing and can be 
explained by the cooperation between TLR4 and TLR2 signaling, as demonstrated by Laflamme and 
colleagues. This cooperation is evident when LPS is injected in TLR2 KO mice. After the first bolus of 
LPS, TLR2 KO mice show a robust signal for genes encoding innate immune proteins in the brain. 
However, the second LPS infusion failed to trigger TNF-α in TLR2 KO mice. These results indicate 
that TLR2 is involved in the second wave of TNF-α expression after LPS and that there is an elegant 
cooperation  between  TLR2  and  TLR4  [112].  Therefore,  it  is  possible  that  the  development  of 
metabolic diseases occurs through TLR2 and TLR4 after LPS stimuli, leading to a proinflammatory 
state and impairment of the insulin signaling. 
High-fat feeding has also been correlated with increase in Gram-negative/Gram-positive ratio [12]. 
These findings also support the thought that intestinal microbiota could be responsible for changes in 
metabolic state, leading to endotoxemia and metabolic diseases. Treating high-fat diet-fed mice with 
antibiotics  reduced  normal  plasma  LPS  values,  reducing  the  occurrence  of  adipose  tissue 
inflammation, oxidative stress and macrophage markers, as well as preventing adipocyte hypertrophy 
and improving metabolic parameters of diabetes and obesity in high-fat diet-fed mice [11].  
This way, dietary fats can be associated with increased absorption of LPS, which might be related 
to  changes  in  the  gut  microbiota,  characterized  by  reduction  in  Gram-negative  Bacteroides-like 
bacteria, in the Eubacterium rectale-Clostridium coccoides group, and in Bifidobacteria [113,114]. Nutrients 2013, 5  838 
 
 
Figure 3. Metabolic endotoxemia leads to activation of insulin resistance in muscle, liver, 
adipose tissue and hypothalamus through activation of Toll-like receptor (TLR)2 and 4. 
JNK: c-Jun N-terminal kinase; IKK: IκB kinase; LPS: lipopolysaccharide; MD-2: myeloid 
differentiation factor-2.  Figure 3
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Although  it  is  generally  assumed  that  insoluble  cereal  fiber  has  beneficial  effects  that  arise  from 
chronic  intake  and  its  subsequent  fermentation  in  the  colon  [114–118],  the  explanation  for  its 
consequent reduction of diabetes risk is still unclear. A study shows that in the first six weeks of  
high-cereal  fiber  (HCF)  diet  administration  for  overweight  patients,  an  increase  in  the  insulin 
sensitivity is observed. However, after 18 weeks, no significant differences are observed compared to 
control and high-protein diet [119]. Moreover, the HCF diet effects observed in whole body insulin 
sensitivity were not accompanied by changes in the composition of the gut microbiota neither after  
6  weeks  nor  after  18  weeks  of  diet  administration  [120].  Therefore,  other  mechanisms  might  be 
responsible  for  these  effects.  After  18  weeks,  prevention  of  aminoacid-induced  activation  of 
mTOR/S6K1 is one of the possible explanations for these results [119,120].  
It is also relevant to state that most of the results with administration of diets or drugs are usually 
obtained from short-term studies, which hampers the transposition of conclusions to humans with 
dietary  habits  carried  on  for  most  of  their  lives.  For  instance,  the  metabolic  effects  of  guar  gum 
consumption can be completely opposite depending of the duration of its administration [121,122]. 
In addition, it is unclear whether results obtained from studies using animal models can be applies 
to humans since they present differences regarding the composition of gut microbiota and diet.  Nutrients 2013, 5  839 
 
 
6. Other Bacterial Factors may Contribute to Insulin Resistance 
Other bacterial factors may play a role in the development of the insulin resistance. Like TLRs, 
nucleotide  oligomerization  domain  (NOD)-1  and  -2  proteins  are  intracellular  pattern  recognition 
receptors  that  sense  bacterial  cell  wall  peptidoglycan  (PGN)  moieties,  which  induce  stress  and 
inflammation  pathways.  NOD1  detects  PGN  structures  found  in  gram-negative  bacteria,  whereas 
NOD2  detects  PGN  segments  typically  found  in  gram-positive  strains  [123].  Recent  studies  have 
associated  NOD1-  and  NOD2-activating  bacterial  motifs  with  insulin  resistance.  Administering  
PGN-based NOD1 activator to adipocytes leads to activation of inflammatory programs, impairing 
insulin signaling and decreasing insulin-stimulated glucose uptake [124]. Likewise, PGN motifs that 
act on NOD2 induce muscle cell-autonomous insulin resistance [125]. NOD1-activating bacterial PGN 
motifs  can  also  cause  acute  systemic  insulin  resistance  in  mice  [126].  This  NOD1  activation 
suppressed  insulin  action  in  the  liver  and  in  isolated  hepatocytes,  and  decreased  insulin-mediated 
glucose uptake in  adipocytes  [126]. Therefore,  NOD1 ligand-mediated  insulin  resistance seems  to 
involve  crosstalk  between  cells  from  different  tissues,  likely  adipose  and  hepatic,  with  indirect 
manifestation in skeletal muscle [123]. 
It is possible that many levels of regulation for NOD1-mediated sensing of PGN take place during 
obesity, since NOD1 transcripts were increased in epididymal adipose tissue of mice fed with high-fat 
diet  [124].  It  remains  to  be  elucidated  whether  these  NOD1  ligands,  possibly  derived  from  the  
gut microbiota, are altered during obesity and the extent of their contribution for the development of  
insulin resistance.  
Amar and colleagues have shown that after only one week of high-fat diet, bacterial translocation 
occurs  towards  adipose  tissue  and  blood  where  inflammation  is  induced.  This  translocation  is 
prevented in mice lacking the microbial recognition receptors NOD1 or CD14 [127], suggesting that 
these receptors have important  roles  in  the development  of the low-grade inflammatory state  that 
characterizes insulin resistance. 
Activation of TLR9 is another possible route by which bacterial components may contribute to 
development  of  other  metabolic  diseases.  TLR9  recognizes  bacteria-derived  cytosine  phosphate 
guanine (CpG)-containing DNA, activating innate immunity. Studies using TLR9 knockout mice have 
stated  the  relevance  of  this  receptor  in  the  development  of  non-alcoholic  fatty  liver  disease, 
steatohepatitis and fibrosis. When its expression is ablated, suppression of IL-1β secretion and reduced 
steatohepatitis and fibrosis are observed. Together with TLR4, TLR9 leads to enhanced hepatic TNF-α 
expression and to the development of non-alcoholic steatohepatitis progression [128,129]. 
7. Intestinal Permeability and the Metabolic Endotoxemia 
An important issue is how dietary fat increases LPS absorption. One explanation would be that LPS 
enters the body by transcellular transport through intestinal epithelial cells, which could occur through 
intestinal-epithelial  microfold  cells  (M-cells).  These  cells  are  permeable  to  bacteria  and 
macromolecules, and are responsible for helping sample gut  antigens by the underlying lymphoid 
tissue [130].  Nutrients 2013, 5  840 
 
 
It has also been reported that TLR is expressed on the apical surface of enterocytes, where it is 
capable  of  binding  and  internalizing  purified  endotoxin  [131–133].  Neal  and  colleagues  have 
demonstrated that enterocytes can internalize Gram-negative bacteria through TLR4, which mediates 
phagocytosis and translocation of Gram-negative bacteria in vivo [134]. LPS absorption might include 
internalization by enterocytes through myeloid differentiation protein-2 (MD-2)-dependent mechanism 
as well [134–136]. 
LPS can also be internalized by intestinal epithelial cells and transported to Golgi compartment  
of  the  enterocyte,  where  newly  assembled  chylomicrons  are  located  before  their  basolateral  
secretion [137,138]. Recent reports have also suggested that diet may play an important role since LPS 
absorption from the gut was found to be associated with the ingestion of dietary fat [12,139]. Because 
the Golgi is a major compartment in chylomicron transport to the basolateral membrane [138,140,141] 
and because LPS has great affinity for chylomicrons [142], a study has raised the possibility that LPS 
could be associated with chylomicrons within the enterocyte [143], being LPS then secreted from  
cell-associated pools in a chylomicron-dependent manner. 
Another possibility is that dietary fat leads to paracellular leakage of LPS across the intestinal 
epithelium. This is supported by the observation that intestinal tight-junction integrity is impaired in 
obese mice [144] and by studies in which intestinal luminal exposure to oleic acid can cause intestinal 
epithelial damage [145,146]. 
Studies  showed  that  TLR2  regulates  tight  junction  (TJ)-associated  intestinal  epithelial  barrier 
integrity and that TLR2 deficiency predisposes to alterations of TJ-modulated barrier function leading 
to perpetuation of mucosal inflammation  [147,148]. Following this direction, we have shown that 
TLR2  KO  mice  present  increased  LPS  absorption,  as  demonstrated  by  LPS  oral  administration 
challenge, due to decreased expression of TJ protein zonula occludens (ZO)-1 in the ileum, which 
leads  to  increased  gut  permeability.  Improvement  of  gut  permeability  has  been  associated  with 
increase  in  Bifidobacterium  spp.,  with  higher  expression  of  tight-junction  proteins  [149].  In  our 
investigations, we have also observed that TLR2 KO mice presented decrease in Bifidobacterium spp., 
supporting the lower  expression of ZO-1. After gut  microbiota transplantation  from  TLR2 KO to 
Bacillus-monoassociated WT mice, we observed that a reduction in the expression of ZO-1 in the 
ileum occurred in the recipients, suggesting that the expression of this protein is regulated by the 
particular microbiota present in the gastrointestinal tract of TLR2 KO mice [46] (Figure 4).  
In the situation in which there is increased intestinal permeability and increased absorption of LPS, 
a state of metabolic endotoxemia is initiated, characterized by elevated serum LPS concentration, but 
still 10–50 times lower than values that could be reached in septicemia or other infections [12]. The 
origin of metabolic endotoxemia is still unclear, but it is strongly suggested that is may be associated 
with changes in the gut microbiota, leading to increased activation of inflammatory pathways and 
impairment of the insulin signaling. Nutrients 2013, 5  841 
 
 
Figure  4. Alteration of intestinal permeability after change in  gut microbiota of obese 
individuals. LPS: lipopolysaccharide; TLR: Toll-like Receptor; ZO-1: zonula occludens. 
 
8. Conclusions 
Environmental  alterations  have  been  shown  as  important  factors  in  the  development  of  many 
diseases. Obesity and insulin resistance are long known for being mainly influenced by a positive 
balance between food intake and energy expenditure. In the past five years, a new component that has 
both genetic and environmental factors has also being associated with the development of obesity: the 
gut  microbiota.  It  can be both  altered by diet  changes  or drug  exposition and by  genetic factors. 
Likewise, it may also influence the expression of host’s proteins and enzymes, as well as its active 
biochemical pathways, directly or through their products of fermentation. These interactions are still 
poorly understood, although metagenomic tools have provided an enormous amount of data concerning 
the characterization of microbiota from different parts of the host’s body in different conditions.  
Changes in bacterial phyla proportions during obesity have captured science attention worldwide, 
especially  because  of  their  effects  on  metabolism.  Increased  proportion  of  Firmicutes  and 
Actinobacteria and decreased proportion of Bacteroidetes have been associated with increased serum 
LPS levels, insulin resistance, increased body weight  gain and other comorbities of the metabolic 
syndrome. The mechanisms that underlie this regulation are still unclear, but their unrevealing brings 
potential interventions for the treatment of obesity and type 2 diabetes.  
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